代表番号

092-541-3231 092-557-6100

受付時間 : 平日 8:30~17:15

予約センター

092-541-3262

受付時間 : 平日 8:30~16:00

新患受付時間 8時30分~11時
休診日 土・日・祝日
年末年始
面会時間 平日:14時~19時
休診日:11時~19時
アクセス 交通アクセス
GoogleMap 地図
お問い合わせはコチラ







ホーム > English > Departments > Department of Pediatrics

Department of Pediatrics

Summary of Department

Our basic policy is to treat pediatric patients and their families with heartfelt care. In cooperation with nurses, physical therapists, psychologists, pharmacists and many other staff members in our hospital, we offer safe and secure medical care. Our clean ward has a playroom and elementary and junior high school classrooms, and we offer child-care and education support during hospitalization treatment.

We have been working as the secretariat of the Kyushu Yamaguchi Childhood Cancer Study Group (KYCCSG) and conducted trials on acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and non-Hodgkin's lymphoma (NHL). In the KYCCSG ALL-02 protocol from 2002-2008, the probabilities of the overall survival and event free survival were 90% and 80%, respectively. While these outcomes were better than before, any of childhood cancers were so rare that uniform clinical trials were required throughout Japan. In 2003, the Japanese Pediatric Leukemia Study Group (JPLSG) was established, and patients have been treated with nationwide protocols. Furthermore, the Japanese Children’s Cancer Group (JCCG) was established in 2014, and more than 200 institutions have participated in its associated clinical trials.

Main scope of the treatment

Main target diseases:

1) Hematological malignancies: ALL, AML, chronic myelogenous leukemia, NHL, etc.
2) Solid tumors: osteosarcoma, Ewing’s sarcoma, rhabdomyosarcoma, etc.
3) Others: aplastic anemia, immune thrombocytopenia purpura, etc.

Treatment:

We treat childhood cancer patients mainly with multi-agent chemotherapy under protocol regimens established by clinical trials.
1) Our department is a member of both the JPLSG and JCCG and participates in nationwide clinical trials
2) We have participated in two investigator-initiated clinical trials in the past year in order to help the following agents receive approval for administration to children:

  • Phase II study of Bortezomib for relapsed ALL
  • Phase I study of Inotuzumab Ozogamicin for relapsed/refractory CD22-positive ALL.